NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in epilepsy treatment trading at $10.67 per share, announced today that it anticipates minimal impact from tariffs on its operations and financial results for fiscal year 2025. Despite experiencing a significant 15% decline over the past week, the company, which manufactures the majority of its devices within the United States, has limited its supply chain activities outside the U.S. for its RNS System, a treatment for epilepsy.
The company also expects no material effect on the gross margin for DIXI Medical SEEG products, which are used for stereoelectroencephalography, a diagnostic procedure for epilepsy. With an impressive gross profit margin of 74% in the last twelve months and revenue growth of 22%, this outlook supports the company’s reiterated gross margin guidance for the year.
NeuroPace previously disclosed the termination of its SEEG distribution agreement with DIXI Medical, effective October 1, 2025, with a six-month wind-down period extending into the first quarter of 2026. Despite this change, the company anticipates maintaining its financial performance.
In addition, NeuroPace will report its first quarter financial results for 2025 on May 13, 2025, after the market closes. With four analysts recently revising earnings estimates upward for the upcoming period, investors are closely watching this announcement. A conference call hosted by the company’s management is scheduled to follow the release of the financial results, providing further insights into the company’s performance and outlook.
The company’s RNS System is touted as the first and only brain-responsive platform available commercially for the treatment of seizures at their source. With a market capitalization of $350 million and projected revenue growth of 18% for fiscal year 2025, NeuroPace aims to establish the RNS System as the standard of care for patients with drug-resistant epilepsy, potentially expanding its application to other brain disorders.
Investors and interested parties can access the conference call via a live and archived webcast, or by dialing in with the provided details. The archived webcast will be available for replay on the company’s investor relations website for at least 90 days following the event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.